Merck KGaA (XSWX:MER)
CHF 130.3 +5.05 (+4.03%) Market Cap: 58.33 Bil Enterprise Value: 66.02 Bil PE Ratio: 24.98 PB Ratio: 2.13 GF Score: 83/100

Q3 2024 Merck KGaA Earnings Call Transcript

Nov 14, 2024 / 01:00PM GMT

Key Points

Positve
  • Merck KGaA (MKGAF) achieved a strong Q3 with 4% organic growth at the group level, driven by all three sectors.
  • Healthcare was the best-performing sector with 6% organic sales growth, supported by innovative franchises.
  • Electronics showed organic sales growth of 2%, driven by semiconductor solutions with a 7% year-on-year growth.
  • EBITDA pre increased by 12% to EUR1.618 billion, despite a 5 percentage point currency headwind.
  • The company confirmed its 2024 sales and earnings target corridors, indicating confidence in future performance.
Negative
  • Currency headwinds negatively impacted reported sales and EBITDA pre by 2% and 5%, respectively.
  • Life Science Services experienced a 17% organic sales decline, impacted by high base comparisons.
  • North America showed a slight organic sales decline of 0.6%, with life science sales slightly lower.
  • The DS&S business in Electronics faced a decline due to project delays, impacting overall performance.
  • Bavencio sales in Healthcare were slightly down due to increasing competition in the US market.
Operator

Dear, ladies and gentlemen, welcome to the Merck investor and analyst conference call on third quarter 2024. (Operator Instructions) I am now handing over to Constantin Fest, Head of Investor Relations, who will lead you through the conference. Please go ahead, sir.

Constantin Fest
Merck KGaA - Head of Investor Relations

Thank you very much, Heidi. A very warm welcome to this Merck Q3 2024 results call. My name is Constantin Fest. I'm Head of Investor Relations here at Merck.

Today, I'm delighted to be joined by Belén Garijo, Group CEO; as well as Helene von Roeder, Group CFO. For the Q&A part of this call, Matthias called in sick and Sebastian Arana, Head of Process Solutions was in Germany and could join on short notice. We're delighted to have him with us covering process solutions questions. Science & Lab Solutions and Life Science Services will be covered by Belén and Helena. Also joining for the Q&A of this call, we have Peter Guenter, CEO of Healthcare; as well as Kai Beckmann, CEO of Electronics.

We would now like to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot